HYBIO(SZ:300199)2022-12-06 08:24Group 1: Product Overview - Carboprost is a synthetic long-acting oxytocin analog used to enhance uterine contractions during cesarean sections, preventing uterine atony and postpartum hemorrhage [2] - In China, approximately 16.5 million newborns are born annually, with an expected increase of 2.5 million newborns per year after the full implementation of the two-child policy [2] - The cesarean section rate is around 45%, indicating a market potential of 2-4 billion RMB for Carboprost, as each cesarean section patient may require 1-2 doses [2] Group 2: Market Impact - The approval of Carboprost and its injection formulation by the National Medical Products Administration in February 2016 has diversified the company's core product offerings [2] - The introduction of Carboprost is expected to significantly enhance the company's performance and optimize its product structure [2] Group 3: Collaboration and Development - The non-invasive continuous glucose monitoring wristband project, in collaboration with Pudi Medical, utilizes near-infrared and bio-resistance signals to provide real-time glucose data, improving the quality of life for diabetes patients [3] - Clinical trials for the glucose monitoring wristband are actively progressing in Europe, with ongoing optimizations based on trial feedback [3] Group 4: Production Expansion - The biopharmaceutical production base in Wuhan has commenced construction, covering an area of 342 acres with a planned building area of 250,000 square meters [3] - The project includes a peptide raw material production base, a high-end solid preparation production base, a national-level biopharmaceutical R&D production base, and an administrative service center [3]